Results 161 to 170 of about 4,040 (201)
Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination [PDF]
Expert Review of Anti-Infective Therapy, 2020 infections due to carbapenem-resistant Enterobacterales (CRE) constitute a worldwide threat and are associated with significant mortality, especially in fragile patients, and costs. Meropenem-vaborbactam (M/V) is a combination of a group 2 carbapenem with a novel cyclic boronic acid-based β-lactamase inhibitor which has shown good efficacy against KPC ...
Andrea Novelli +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
International Journal of Antimicrobial Agents, 2018
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Michael D Huband, Mariana Castanheira
exaly +3 more sources
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Michael D Huband, Mariana Castanheira
exaly +3 more sources